DxS, a personalised medicine company, and Boehringer Ingelheim have entered into an agreement to provide a companion diagnostic test kit for Boehringer Ingelheim’s compound BIBW 2992 to identify mutations of the EGFR (epidermal growth factor receptor) in patients with non small cell lung cancer. Financial terms of the agreement are not disclosed.
The DxS EGFR companion diagnostic is a real-time PCR assay, designed to detect the most common mutations in the EGFR gene.
Protea Biosciences announced today that it has entered into a drug development partnership with LABORATOIRES MAYOLY SPINDLER , a European pharmaceutical company based in France, that specializes in Gastroenterology therapeutics.
Mayoly has developed a recombinant Lipase, an enzyme for the treatment of exocrine pancreatic insufficiency. EPI is a condition where there is a lack of digestive enzymes made by the pancreas that results in the inability to properly digest food and absorb nutrients.
Under terms of the agreement, Protea will receive the exclusive marketing rights for the recombinant Lipase biopharmaceutical for North America.
Affiliated Computer Services and Novell have announced a strategic partnership to expand their core technical capabilities and suite of services. As part of the partnership, Novell will outsource part of its internal IT operations to ACS, which will also provide SAP consulting and applications development and maintenance system integration services as part of a $135 million, five-year contract. ACS will also partner with Novell to enhance its global data center operations and will purchase at least $30 million in Novell products during the first three years of the partnership.
eChannelLine is reporting that Brocade has unveiled its new global Alliance Partner Network channel program, designed to attract storage and IP networking channel resellers with a more selective, profitable alternative to existing channel programs.
RaySearch Laboratories AB has entered into a long-term development and licensing agreement with Siemens Healthcare. Under the terms of the collaboration RaySearch will provide a number of treatment planning modules aimed at improving radiation therapy. The software modules will be integrated in Siemens’ syngo Suite for Oncology, which is Siemens’ integrated workflow solution for radiation therapy. The collaboration is expected to start generating revenues for RaySearch during 2011.
FUJIFILM Corporation has announced that it has entered into a Strategic Alliance Agreement with GE Healthcare. Under the alliance, Fujifilm will develop, manufacture and supply advanced biomolecular imaging systems to GE Healthcare. The products will be sold worldwide under the GE brand in the life science research and drug discovery markets.
Britain’s Office of Fair Trading will investigate the plans by GlaxoSmithKline to pool resources with Pfizer Inc. to create a new company to develop and sell HIV medicines. The OFT will decide whether the joint venture can be considered to be a merger that will reduce competition in the UK. It also will decide whether to refer the case to the Competition Commission regulators, which have the power to block or put limits on the deal. The OFT said interested parties had until June 9 to submit their views for the first stage of consultations. Full story here.
Galapagos NV has announced today achievement of a milestone under its alliance agreement in rheumatoid arthritis with Janssen Pharmaceutica NV. The milestone triggered a cash payment of EUR 3.4 million to Galapagos.
Sanofi-aventis and Exelixis Inc have announced a global license agreement for XL147 and XL765 and a broad collaboration for the discovery of inhibitors of phosphoinositide-3 kinase for the treatment of cancer. Under the license, sanofi-aventis will have a worldwide exclusive license to XL147 and XL765, which are currently in phase 1 and phase 1b/2 clinical trials, and will have sole responsibility for all subsequent clinical, regulatory, commercial and manufacturing activities. Exelixis will participate in conducting ongoing and potential future clinical trials and manufacturing activities.
Sanofi-aventis will pay Exelixis aggregate upfront cash payments of $140 million under the license and collaboration. Exelixis will also receive guaranteed research funding of $21 million over a three year research term under the collaboration. For the license and the collaboration, Exelixis will be eligible to receive development, regulatory and commercial milestones of over $1 billion in the aggregate, as well as royalties on sales of any products commercialized under the license or collaboration.